Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
Overview. This is a summary of the European public assessment report (EPAR) for Evra. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Evra.
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). o Summary of Product Characteristics (SmPC) before pre. embolism (VTE), and how the risk of VTE with EVRA. compares with other CHCs (see contraindications and special warn. Adults: Transdermal use. One patc. for 7 days, for 3 weeks followed by 1 week patch free. .
EVRA is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years. The decision to prescribe EVRA should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with EVRA
ORTHO EVRATM is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE), and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
23 Απρ 2024 · Generic name: norelgestromin 150ug in 1d, ethinyl estradiol 35ug in 1d. Dosage form: patch, extended release. Drug class: Contraceptives. Medically reviewed by Drugs.com. Last updated on Apr 23, 2024. To achieve maximum contraceptive effectiveness, ORTHO EVRA must be used exactly as directed.
